Circadian Technologies (ASX:CIR) has raised $17.4m through a placement and share purchase plan, and plans to use the proceeds to take OPT-302 into the clinic in wet AMD. [ + ]

GI Dynamics (ASX:GID) has received the all-clear to resume shipments of its EnBobarrier obesity and diabetes therapy in the EU following a two-month suspension. [ + ]

Genetic Technologies (ASX:GTG) has announced the resignation of CEO Alison Mew, and has secured shareholder approval to change its name to Phenogen Sciences. [ + ]

EY has released its annual medical technology report for 2014 - 'Pulse of the industry: differentiating differently'. [ + ]

Novogen (ASX:NRT) has selected the lead candidate from its family of drugs designed to complement existing chemotherapies by targeting a different part of a cancer's cytoskeleton. [ + ]

Bioprinted liver tissue containing both parenchymal and non-parenchymal cells in spatially controlled, user-defined geometries that reproduce compositional and architectural features of native tissue are making it possible to assess drug effects over timeframes much longer than those offered by 2D liver cell culture systems.

CSL (ASX:CSL) has launched a trial of CSL112 in patients at risk of recurrent cardiovascular events and presented data into the cholesterol-clearing mechanism of action behind the drug. [ + ]

Genetic Technologies (ASX:GTG) has completed the sale of its Australian genetics business to Specialist Diagnostics Services as part of its streamlining efforts. [ + ]

Researchers at ETH Zurich have created the first gene network to be operated via brainwaves. Depending on the user's thoughts, it can produce various amounts of a desired molecule.

In March 2004, the spacecraft Rosetta was launched by the European Space Agency - its mission to orbit and land on the comet 67P/Churyumov-Gerasimenko. To complete the most detailed study of a comet ever attempted, the orbiter carried 11 science experiments and its lander, Philae, carried 10 additional instruments. [ + ]

Alchemia (ASX:ACL) has announced the sudden departure of CEO Thomas Liquard, Calzada (ASX:CZD) has appointed a new CEO and Patrys (ASX:PAB) has added to its board. [ + ]

CSL (ASX:CSL) has completed a debt placement worth nearly $500m to help pay for capital management activities including its $900m share buyback. [ + ]

An international research collaboration has built a pathway that makes brain-to-brain communication possible - with a little help from the internet. [ + ]

With Novogen (ASX:NRT) moving to take anticancer candidate Cantrixil into the clinic, the company is making moves to line up funding and allow it to better focus on clinical development. [ + ]

Australian researchers have discovered how the massive DNA molecules that appear in some tumours are stitched together from other parts of the genome, making them similar to Frankenstein's monster. [ + ]